Treatment Research Study Available for Untreated Hodgkin Lymphoma

Pilot study of abbreviated chemotherapy based on early positron emission tomography in Hodgkin lymphoma

Update: this study is closed to enrollment. 

Patients in this study will be treated with ABVD (adriamycin, bleomycin, vinblastine and dacarbazine) on Days 1 and 15 of each cycle according to standard treatment guidelines.  The purpose of this study is to determine the progression-free survival at 36 months for patients with Hodgkin lymphoma who achieve a response after one cycle of ABVD chemotherapy.

Click here for more information on this study for people with untreated Hodgkin lymphoma or call June Greenberg, RN at (212) 746-2651.

Click here for the clinical and research profile of Rebecca Elstrom, MD, the physician leading the study at Weill Cornell Medical Center.

Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.

Post a Comment

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s